Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1132-3209 | Registry Identifier | WHO | |
| JapicCTI-121916 | Registry Identifier | JapicCTI |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SYR-322 25 mg , AD-4833 15 mg | Experimental |
| |
| SYR-322 25 mg , AD-4833 30 mg | Experimental |
| |
| SYR-322 25 mg , AD-4833 placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AD-4833 15 mg | Drug |
| ||
| AD-4833 30 mg |
| Measure | Description | Time Frame |
|---|---|---|
| Glycosylated Hemoglobin (HbA1c) | Measurement of change in HbA1c (ratio of hemoglobin bound to glucose) | 16 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Study Director | Takeda (Note: This product was divested to Teijin Pharma Limited in 2023) | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hirosaki-shi | Aomori | Japan | ||||
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug |
|
| Kisaratsu-shi |
| Chiba |
| Japan |
| Matsuyama | Ehime | Japan |
| Fukuoka | Fukuoka | Japan |
| Kitakyushu-shi | Fukuoka | Japan |
| Kurume-shi | Fukuoka | Japan |
| Fukuyama-shi | Hiroshima | Japan |
| Hiroshima | Hiroshima | Japan |
| Sapporo | Hokkaido | Japan |
| Koga-shi | Ibaraki | Japan |
| Yokohama | Kanagawa | Japan |
| Kumamoto | Kumamoto | Japan |
| Miyazaki | Miyazaki | Japan |
| Suita-shi | Osaka | Japan |
| Koshigaya-shi | Saitama | Japan |
| Ōtsu | Shiga | Japan |
| Chiyoda-ku | Tokyo | Japan |
| Chuo-ku | Tokyo | Japan |
| Itabashi-ku | Tokyo | Japan |
| Meguro-ku | Tokyo | Japan |
| Minato-ku | Tokyo | Japan |
| Ohta-ku | Tokyo | Japan |
| Shinjuku-ku | Tokyo | Japan |
| Toyama | Toyama | Japan |
| Shimonoseki-shi | Yamaguchi | Japan |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077205 | Pioglitazone |
| ID | Term |
|---|---|
| D045162 | Thiazolidinediones |
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided